🚫💊 Should We Rethink Beta-Blockers Post-MI?

In the landmark REBOOT trial (NEJM, 2025), beta-blockers failed to reduce mortality, reinfarction, or heart failure hospitalizations in post-MI patients with preserved ejection fraction (>40%).

💡 A modern, pragmatic trial across 109 centers (Spain + Italy 🇪🇸🇮🇹) with 8438 patients — shaking the foundation of our long-held post-MI practices.

👩‍⚕️ Signals of potential harm in women and STEMI subgroups raise questions, not answers.

📉 Should guidelines change? Or should practice just evolve?

#Cardiology #REBOOTTrial #BetaBlockers #NEJM #PrecisionMedicine #MedicalEducation #HeartAttack #LVEF #Guidelines #ClinicalTrials #InternalMedicine #EvidenceBasedMedicine #Revascularization